Siglec-8 and siglec-F

Inhibitory receptors on eosinophils, basophils, and mast cells

Jin P. Guo, Esra Nutku, Hidenori Yokoi, Ronald Lee Schnaar, Nives Zimmermann, Bruce S. Bochner

Research output: Contribution to journalArticle

Abstract

Background: Sialic acid binding immunoglobulin (Ig)-like lectins (Siglecs) are a family of inhibitory surface receptors expressed primarily by leukocytes. Among these, Siglec-8 is exclusively expressed on human eosinophils, mast cells and basophils. Its closest functional paralog in the mouse is Siglec-F. The function of these receptors on these cells is just now being examined. Methods/Data base: Various in vitro experiments involving' purified human cells, cells grown from CD34+ precursors, cell lines, and in vivo mouse models are being employed along with specific anti-Siglec antibodies to define signaling function. Functional glycomic approaches are being used to screen for candidate glycan ligands for these Siglecs. Results: Siglec-8 or Siglec-F engagement on eosinophils by antibodies induces apoptosis in vitro. Siglec-8 engagement on human mast cells by antibodies does not induce apoptosis but does inhibit mediator release induced via FcṘI activation. Administration of Siglec-F antibodies to eosinophilic mice reduces circulating and tissue eosinophil levels. Screening using Siglec-8 and Siglec-F-Ig fusion proteins has identified a common glycan ligand, namely NeuAcα2-3(6-O-sulfo)Galβ 1-4[Fucα1-3]GlcNAc, also referred to as 6′-sulfo-sLex. Conclusions: Ongoing work on Siglec-8, and its paralog Siglec-F, has potential for identifying new therapeutic approaches for the treatment of diseases characterized by increased numbers of, or mediators from, eosinophils, basophils, and mast cells.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalAllergy and Clinical Immunology International
Volume19
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
Basophils
Eosinophils
Mast Cells
Polysaccharides
Antibodies
Glycomics
Apoptosis
Ligands

Keywords

  • Siglec-8
  • Siglec-F

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Siglec-8 and siglec-F : Inhibitory receptors on eosinophils, basophils, and mast cells. / Guo, Jin P.; Nutku, Esra; Yokoi, Hidenori; Schnaar, Ronald Lee; Zimmermann, Nives; Bochner, Bruce S.

In: Allergy and Clinical Immunology International, Vol. 19, No. 2, 03.2007, p. 54-59.

Research output: Contribution to journalArticle

Guo, Jin P. ; Nutku, Esra ; Yokoi, Hidenori ; Schnaar, Ronald Lee ; Zimmermann, Nives ; Bochner, Bruce S. / Siglec-8 and siglec-F : Inhibitory receptors on eosinophils, basophils, and mast cells. In: Allergy and Clinical Immunology International. 2007 ; Vol. 19, No. 2. pp. 54-59.
@article{f3931a834c7d4098ab81db3ef11e9488,
title = "Siglec-8 and siglec-F: Inhibitory receptors on eosinophils, basophils, and mast cells",
abstract = "Background: Sialic acid binding immunoglobulin (Ig)-like lectins (Siglecs) are a family of inhibitory surface receptors expressed primarily by leukocytes. Among these, Siglec-8 is exclusively expressed on human eosinophils, mast cells and basophils. Its closest functional paralog in the mouse is Siglec-F. The function of these receptors on these cells is just now being examined. Methods/Data base: Various in vitro experiments involving' purified human cells, cells grown from CD34+ precursors, cell lines, and in vivo mouse models are being employed along with specific anti-Siglec antibodies to define signaling function. Functional glycomic approaches are being used to screen for candidate glycan ligands for these Siglecs. Results: Siglec-8 or Siglec-F engagement on eosinophils by antibodies induces apoptosis in vitro. Siglec-8 engagement on human mast cells by antibodies does not induce apoptosis but does inhibit mediator release induced via FcṘI activation. Administration of Siglec-F antibodies to eosinophilic mice reduces circulating and tissue eosinophil levels. Screening using Siglec-8 and Siglec-F-Ig fusion proteins has identified a common glycan ligand, namely NeuAcα2-3(6-O-sulfo)Galβ 1-4[Fucα1-3]GlcNAc, also referred to as 6′-sulfo-sLex. Conclusions: Ongoing work on Siglec-8, and its paralog Siglec-F, has potential for identifying new therapeutic approaches for the treatment of diseases characterized by increased numbers of, or mediators from, eosinophils, basophils, and mast cells.",
keywords = "Siglec-8, Siglec-F",
author = "Guo, {Jin P.} and Esra Nutku and Hidenori Yokoi and Schnaar, {Ronald Lee} and Nives Zimmermann and Bochner, {Bruce S.}",
year = "2007",
month = "3",
doi = "10.1027/0838-1925.19.2.54",
language = "English (US)",
volume = "19",
pages = "54--59",
journal = "Allergy and Clinical Immunology International",
issn = "0838-1925",
publisher = "Hogrefe Publishing",
number = "2",

}

TY - JOUR

T1 - Siglec-8 and siglec-F

T2 - Inhibitory receptors on eosinophils, basophils, and mast cells

AU - Guo, Jin P.

AU - Nutku, Esra

AU - Yokoi, Hidenori

AU - Schnaar, Ronald Lee

AU - Zimmermann, Nives

AU - Bochner, Bruce S.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Sialic acid binding immunoglobulin (Ig)-like lectins (Siglecs) are a family of inhibitory surface receptors expressed primarily by leukocytes. Among these, Siglec-8 is exclusively expressed on human eosinophils, mast cells and basophils. Its closest functional paralog in the mouse is Siglec-F. The function of these receptors on these cells is just now being examined. Methods/Data base: Various in vitro experiments involving' purified human cells, cells grown from CD34+ precursors, cell lines, and in vivo mouse models are being employed along with specific anti-Siglec antibodies to define signaling function. Functional glycomic approaches are being used to screen for candidate glycan ligands for these Siglecs. Results: Siglec-8 or Siglec-F engagement on eosinophils by antibodies induces apoptosis in vitro. Siglec-8 engagement on human mast cells by antibodies does not induce apoptosis but does inhibit mediator release induced via FcṘI activation. Administration of Siglec-F antibodies to eosinophilic mice reduces circulating and tissue eosinophil levels. Screening using Siglec-8 and Siglec-F-Ig fusion proteins has identified a common glycan ligand, namely NeuAcα2-3(6-O-sulfo)Galβ 1-4[Fucα1-3]GlcNAc, also referred to as 6′-sulfo-sLex. Conclusions: Ongoing work on Siglec-8, and its paralog Siglec-F, has potential for identifying new therapeutic approaches for the treatment of diseases characterized by increased numbers of, or mediators from, eosinophils, basophils, and mast cells.

AB - Background: Sialic acid binding immunoglobulin (Ig)-like lectins (Siglecs) are a family of inhibitory surface receptors expressed primarily by leukocytes. Among these, Siglec-8 is exclusively expressed on human eosinophils, mast cells and basophils. Its closest functional paralog in the mouse is Siglec-F. The function of these receptors on these cells is just now being examined. Methods/Data base: Various in vitro experiments involving' purified human cells, cells grown from CD34+ precursors, cell lines, and in vivo mouse models are being employed along with specific anti-Siglec antibodies to define signaling function. Functional glycomic approaches are being used to screen for candidate glycan ligands for these Siglecs. Results: Siglec-8 or Siglec-F engagement on eosinophils by antibodies induces apoptosis in vitro. Siglec-8 engagement on human mast cells by antibodies does not induce apoptosis but does inhibit mediator release induced via FcṘI activation. Administration of Siglec-F antibodies to eosinophilic mice reduces circulating and tissue eosinophil levels. Screening using Siglec-8 and Siglec-F-Ig fusion proteins has identified a common glycan ligand, namely NeuAcα2-3(6-O-sulfo)Galβ 1-4[Fucα1-3]GlcNAc, also referred to as 6′-sulfo-sLex. Conclusions: Ongoing work on Siglec-8, and its paralog Siglec-F, has potential for identifying new therapeutic approaches for the treatment of diseases characterized by increased numbers of, or mediators from, eosinophils, basophils, and mast cells.

KW - Siglec-8

KW - Siglec-F

UR - http://www.scopus.com/inward/record.url?scp=34250313269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250313269&partnerID=8YFLogxK

U2 - 10.1027/0838-1925.19.2.54

DO - 10.1027/0838-1925.19.2.54

M3 - Article

VL - 19

SP - 54

EP - 59

JO - Allergy and Clinical Immunology International

JF - Allergy and Clinical Immunology International

SN - 0838-1925

IS - 2

ER -